References
- Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr Allergy 1987;21:1–20
- Abelson MB, George MA, Garofalo C. Differential diagnosis of ocular allergic disorders. Ann Allergy 1993;70:95–109
- Allansmith MR, Ross RN. Ocular allergy. Clin Allergy 1998;18:1–13
- University of Michigan Kellogg Eye Centre 2005. Available online at http://www.kellogg.umich.edu/
- Leonardi A. Pathophysiology of allergic conjunctivitis. Acta Ophthalmol Scand 1999;228(Suppl):21–3
- Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54:451–6
- Anderson DF. Management of seasonal allergic conjunctivitis (SAC): current therapeutic strategies. Clin Exp Allergy 2001;31:823–6
- The Eye Centre 2005. Available online at http://www.theeyecenter.com
- Lafuma A, Smith AF. Cost-effectiveness of olopatadine in seasonal allergic conjunctivitis treatment. Expert Rev Pharmacoeconomics Outcomes Res 2002;2:549–54
- Katelaris CH, Ciprandi G, Missotten L, et al. A comparison of the efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and cromolyn sodium 2% ophthalmic solution in seasonal allergic conjunctivitis. Clin Ther 2002;24:1561–75
- Lafuma A, Fagnani F, Nuijten M, Berdeaux G. Costs and consequences of olopatadine 0.1% versus cromolyn sodium 2% in the treatment of seasonal allergic conjunctivitis. Value in Health 2001a;4:514
- SMC 2006. Scottish Medicines Consortium. Summary of advice on olopatadine eye drops (Opatanol), for use within NHS Scotland. Available on-line at http://www.scottishmedicines.org.uk/press/detail.asp?id=836
- IMS 2005, London
- Netten A, Curtis L. Unit costs of health and social care 2004. University of Kent, Canterbury: Personal Social Services Research Unit; 2004
- NHS Executive Reference Costs 2004. Leeds: Department of Health; 2005
- BNF (British National Formulary). London: BMA and Royal Pharmaceutical Society of Great Britain; 2005
- Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co.; 1980. pp. 228–65
- Pitt AD, Smith AF, Lindsell L, et al. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11:17–33
- Lafuma A, Fagnani F, Nuijten M, Berdeaux G. Costs and consequences of olopatadine 0.1% versus levocabastine 0.05% in the treatment of seasonal allergic conjunctivitis. Value in Health 2001;4:513